Table 3 |
||||
|
Multivariate results of competitor price trends for 19 medicines before and after RPI introduction |
||||
|
Price Trends Before RPI are NOT Equal to Price Trends After RPI |
Price Trends Before RPI are Equal to Price Trends After RPI |
|||
|
|
||||
|
A |
B |
C |
D |
E |
|
Medicine |
Immediate price effect of RPI§ |
Quarterly price trends before RPI |
Quarterly price trends after RPI |
Quarterly price trends before and after RPI |
|
|
||||
|
ampicillin 500 mg injection |
-1.19** |
-0.27** |
0.01 |
|
|
|
||||
|
atenolol 50 mg tablets |
-0.52** |
-0.14* |
-0.05 |
|
|
|
||||
|
metronidazole 250 mg tablets |
-0.35** |
-0.03** |
0.01 |
|
|
|
||||
|
carbamazepine 200 mg tablets |
-1.04* |
-0.22* |
-0.02 |
|
|
|
||||
|
diclofenac 75 mg injection |
-2.33** |
-0.34** |
-0.07 |
|
|
|
||||
|
doxycycline 100 mg capsules |
-1.19** |
-0.08** |
-0.03 |
|
|
|
||||
|
benzylpenicillin 1 g injection |
0.06* |
-0.02** |
||
|
|
||||
|
erythromycin 250 mg tablets |
-0.07 |
-0.01 |
||
|
|
||||
|
amoxicillin 250 mg tablets |
0.20* |
-0.05** |
||
|
|
||||
|
ciprofloxacin 250 mg tablets |
-0.73* |
-0.01 |
||
|
|
||||
|
enalapril 20 mg tablets (Ednyt®) |
-0.18 |
-0.21** |
||
|
|
||||
|
ferrous sulfate+folic acid+ascorbic acid tablets (Gyno-Tardyferon®) |
1.96* |
0.26** |
||
|
|
||||
|
ferrous sulfate+ascorbic acid tablets (Taryferon®) |
1.40 |
0.29** |
||
|
|
||||
|
nifedipine 20 mg retard tablets (Corinafar Retard®) |
0.93* |
-0.06 |
||
|
|
||||
|
prednisolone 5 mg tablets |
0.38 |
-0.10* |
||
|
|
||||
|
diclofenac 25 mg tablets (Ortophen®) |
-0.05 |
-0.01* |
||
|
|
||||
|
metronidazole 500 mg vaginal suppositories |
-4.85** |
-0.27** |
||
|
|
||||
|
omeprazole 20mg capsules |
0.75* |
-0.30** |
||
|
|
||||
|
ketotifen tablets |
0.18 |
-0.08** |
||
|
|
||||
|
§ Difference in competitor price from the quarter before to the quarter after the RPI was introduced *p ≤ 0.05 **p < 0.0001 |
||||
|
Waning et al. International Journal for Equity in Health 2009 8:43 doi:10.1186/1475-9276-8-43 |
||||